The Best Selling Biologic of All Time now chased by New Phase III Biosimilar

04/03/2016 - 2 minutes

Merck (Germany) has initiated a phase III trial for a biosimilar of AbbVie’s Humira, to treat Chronic plaque psoriasis. This is a big deal as Humira is the best selling biologics of all time (over €10Bn in annual revenues).

merck_psoriaris_msb11022_humira_abbvie_adalimunab_phase_III_biosimilarMerck is developing a candidate (MSB11022) as a biosimilar of adalimumab, a human monoclonal antibody sold under the brand Humira – a key asset to AbbVie.

MSB11022 has the same action mechanism, binding the tumour necrosis factor-alpha (TNF-α) – a cell signalling protein produced by cells of the immune system. Blocking TNF-α reduces the inflammation response, and thus could have applications in many inflammatory diseases.

Merck is now advancing with phase III trial (AURIEL-PsO) for Chronic plaque psoriasis. This double-blind study will enrol 406 patients in the US and Germany, and is sponsored by the US arm of Merck, EMD Serono.

Merck expects to have top-line data in the end of 2016.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member